Non-invasive refers to non-invasive DNA prenatal testing technology. The difference between Down’s syndrome screening and non-invasive DNA prenatal testing technology lies in the timing, content and accuracy of the test. 1. Down’s syndrome screening: This test is performed in early pregnancy, i.e. 11 to 13 weeks, or in mid-pregnancy, i.e. 15 to 20 weeks. Down’s syndrome is detected by checking the serum of pregnant women for human chorionic gonadotropin, alpha-fetoprotein, free estriol and other non-specific biochemical indicators. The accuracy rate of Down’s syndrome screening is about 70%. 2. Non-invasive DNA prenatal testing: The test is performed at 12 to 20 weeks of pregnancy and is also suitable for pregnant women who missed the Down’s screening test. Non-invasive DNA prenatal testing technology is mainly used to determine whether the fetus has congenital hereditary diseases by checking the free DNA of the fetus in the peripheral blood of the pregnant woman. The accuracy rate of non-invasive DNA prenatal testing technology is around 90 to 95%. Pregnant women need to go to the hospital on time for relevant checkups when they are pregnant and strengthen maternal health care.